EUCTR2020-004981-20-IT进行中（未招募）1 期
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis. - APEX
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 950
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Be at least 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place).
- •2.Have active PsA despite previous non-biologic DMARD, apremilast, and/or NSAID therapy.
- •3.Have a diagnosis of PsA for at least 6 months prior to the first administration of study intervention and meet ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria at screening.
- •4.Have active PsA as defined by:
- •a.At least three swollen joints and three tender joints at screening and at baseline
- •b. CRP >= 0.3 mg/dL at screening from the central laboratory.
- •NOTE: A one-time repeat assessment of CRP level is allowed during the 6-week screening phase and the investigator may consider the participant eligible if the test result is within acceptable range on repeat testing in the central laboratory.
- •5.Have >= 2 joints with erosions on baseline radiographs of the hands and feet as determined by central read.
- •6.Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis.
- •7.Have active plaque psoriasis, with at least one psoriatic plaque of >= 2cm diameter and/or nail changes consistent with psoriasis.
- •8.If currently using non-biologic DMARDs (limited to MTX, SSZ, HCQ, or LEF), participants should have started treatment at least 3 months and the dose must be stable for at least 4 weeks before first administration of study intervention and should have no serious toxic side effects
- •attributable to the non-biologic DMARD. If currently not using MTX, SSZ, or HCQ, must not have received for at least 4 weeks before first administration of study intervention. If currently not using LEF, must not have received for at least 12 weeks before first administration of study
- •intervention.
- •a.If using MTX, the route of administration and dose must be stable and the dose must be <=25 mg/week.
- •b.If receiving SSZ, the dose must be <=3g/day.
- •c.If receiving HCQ, the dose must be <=400 mg/day.
- •d.If receiving LEF, the dose must be <=20 mg/day.
- •9.If using NSAIDs or other analgesics for PsA at baseline, participants must be on a stable dose for at least 2 weeks prior to the first administration of study intervention. If currently not using NSAIDs or other analgesics for PsA, must not have received NSAIDs or other analgesics for PsA within 2 weeks prior to the first administration of study intervention.
- •10.If using oral corticosteroids at baseline, participants must be on a stable dose equivalent to <=10 mg of prednisone/day for at least 2 weeks prior to the first administration of study intervention. If not currently using oral corticosteroids, the participant must not have received oral corticosteroids within 2 weeks prior to the first administration of study intervention.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 893
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •1.Has known allergies, hypersensitivity, or intolerance to study intervention or its excipients.
- •2.Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to RA, axial spondyloarthritis (AS)/non-radiographic axial spondyloarthritis (nraxSpA), systemic lupus erythematosus, or Lyme disease (confirmed by Western blot).
- •3.Has the arthritis mutilans subset of PsA.
- •4.Has previously received any biologic treatment including, but not limited to, guselkumab, ustekinumab, secukinumab, anti-TNFa agents (such as adalimumab, etanercept, infliximab, golimumab SC or intravenous (IV), certolizumab pegol, or their respective biosimilars), tildrakizumab, ixekizumab, brodalumab, risankizumab or other investigative biologic treatment for PsA or psoriasis.
- •5.Has ever received tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other Janus kinase (JAK) inhibitor.
- •6.Has received any systemic immunosuppressants (eg, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention.
- •7.Has received non-biologic DMARDs other than MTX, SSZ, HCQ, LEF, within 4 weeks before the first administration of study intervention.
- •8.Is receiving 3 or more non-biologic DMARDs specified in Table 3 at baseline. Note: participants cannot be on concomitant MTX and LEF.
- •9.Has received phototherapy or any systemic medications/treatments that could affect psoriasis evaluations (including, but not limited to, retinoids, 1,25-dihydroxy vitamin D3 and analogues, psoralens, fumaric acid derivatives, with the exception of those in Table 3) within 4 weeks of the first administration of study intervention.
研究者
相似试验
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic ArthritisPsoriatic arthritis (PsA)MedDRA version: 21.0Level: LLTClassification code: 10037160Term: Psoriatic arthritis Class: 10028395CTIS2023-504734-21-00Janssen - Cilag International967
进行中（未招募）
1 期
A study to evaluate the safety of Pimavanserin Therapy in subjects With Neuropsychiatric Symptoms related to neurodegenerative disease.europsychiatric Symptoms Related to Neurodegenerative DiseaseMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-003536-36-ROACADIA Pharmaceuticals Inc.300
进行中（未招募）
1 期
Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Sequential TherapyPostmenopausal osteoporosisEUCTR2017-000675-90-LTAmgen Inc.150
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic ArthritisEUCTR2020-004981-20-ESJanssen-Cilag International NV950
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic ArthritisPsoriatic arthritis (PsA)MedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2020-004981-20-LVJanssen-Cilag International NV950